Exact Sciences launched Cancerguard, a liquid biopsy test designed to detect signals from 50 different cancer types, expanding beyond established screenings for breast, lung, and colorectal cancers. Available nationwide at $689, the test aims to enable earlier diagnosis when therapies are more effective. The launch represents a significant step in the multi-cancer early detection (MCED) market, addressing a major gap in cancer screening by leveraging circulating tumor DNA and epigenetic markers.